Acne
Actinic Keratosis
Aesthetics
Alopecia
Atopic Dermatitis
Buy-and-Bill
COVID-19
Case-Based Roundtable
Chronic Hand Eczema
Drug Watch
Eczema
General Dermatology
Hidradenitis Suppurativa
Melasma
NP and PA
Pediatric Dermatology
Pigmentary Disorders
Practice Management
Precision Medicine and Biologics
Prurigo Nodularis
Psoriasis
Psoriatic Arthritis
Rare Disease
Rosacea
Skin Cancer
Vitiligo
Wound Care

Article

September 1, 2003

RADIOTHERAPY GRANT

AlphaMed Inc. announced that it received a $500,000 two-year STTR Phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!

Related Videos

Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters

Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD

The Future of Pediatric Care at MOPD

Updates on Treating Warts, Molluscum Contagiosum, and Other Pediatric Conditions

A Talk with Albert Yan, MD on Current Trends in Technology

An Analysis of Gender Differences in 4645 cases of Pediatric and Adolescent Melanoma

Sneak Peek at Best Sessions on Sunday at the Society for Pediatric Dermatology Meeting

Talking with Amy Paller, MD, about the Society for Pediatric Dermatology Meeting

Acne: Therapeutic Updates and Our Most Challenging Cases

Candrice Heath, MD, Discusses Her Presentation on Atopic Dermatitis in Skin of Color

RADIOTHERAPY GRANT

Newsletter